Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

2.800 +0.500 (+21.74%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 Next >
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
Company to Hold Clinical Update Webcast; Details Forthcoming 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Second Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Highlights from Clinical Update
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Provides Update on Reverse Stock Split
Common Shares to begin trading on adjusted basis June 6 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the First Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
From Aptose Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.